Results 31 to 40 of about 25,220 (171)

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs

npj Vaccines, 2022
Abstract Recombinant vesicular stomatitis viruses (rVSVs) engineered to express heterologous viral glycoproteins have proven to be remarkably effective vaccines. Indeed, rVSV-EBOV, which expresses the Ebola virus (EBOV) glycoprotein, recently received clinical approval in the United States and Europe for its ability to prevent EBOV ...
Wenguang Cao, Shihua He, Guodong Liu, Helene Schulz, Karla Emeterio, Michael Chan, Kevin Tierney, Kim Azaransky, Geoff Soule, Nikesh Tailor, Abdjeleel Salawudeen, Rick Nichols, Joan Fusco, David Safronetz, Logan Banadyga   +14 more
openaire   +3 more sources

Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection

iScience, 2020
Summary: The 2014–2016 West Africa Ebola virus (EBOV) outbreak coupled with the most recent outbreaks in Central Africa underscore the need to develop effective treatment strategies against EBOV.
Yangsheng Yu, Christopher L. Cooper, Guangshun Wang, M. Jane Morwitzer, Krishna Kota, Julie P. Tran, Steven B. Bradfute, Yan Liu, Jiayu Shao, Amanda K. Zhang, Lindsey G. Luo, St. Patrick Reid, Steven H. Hinrichs, Kaihong Su   +13 more
doaj   +1 more source

Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications

Viruses, 2016
The 2014 outbreak of Ebola virus (EBOV) in Western Africa highlighted the need for anti-EBOV therapeutics. Clomiphene is a U.S. Food and Drug Administration (FDA)-approved drug that blocks EBOV entry and infection in cells and significantly protects EBOV-
Elizabeth A. Nelson, Alyson B. Barnes, Ronald D. Wiehle, Gregory K. Fontenot, Thomas Hoenen, Judith M. White   +5 more
doaj   +1 more source

Systematic Genome-wide Screening and Prediction of microRNAs in EBOV During the 2014 Ebolavirus Outbreak [PDF]

Scientific Reports, 2015
AbstractRecently, several thousand people have been killed by the Ebolavirus disease (EVD) in West Africa, yet no current antiviral medications and treatments are available. Systematic investigation of ebolavirus whole genomes during the 2014 outbreak may shed light on the underlying mechanisms of EVD development.
Teng, Yue, Wang, Yuzhuo, Zhang, Xianglilan, Liu, Wenli, Fan, Hang, Yao, Hongwu, Lin, Baihan, Zhu, Ping, Yuan, Wenjun, Tong, Yigang, Cao, Wuchun   +10 more
openaire   +2 more sources

The Ebola virus soluble glycoprotein contributes to viral pathogenesis by activating the MAP kinase signaling pathway.

PLoS Pathogens, 2021
Ebola virus (EBOV) expresses three different glycoproteins (GPs) from its GP gene. The primary product, soluble GP (sGP), is secreted in abundance during infection. EBOV sGP has been discussed as a potential pathogenicity factor, however, little is known
Wakako Furuyama, Kyle Shifflett, Heinz Feldmann, Andrea Marzi   +3 more
doaj   +1 more source

An update on the risk of transmission of Ebola virus (EBOV) via the food chain [PDF]

EFSA Journal, 2014
Abstract Several animal species were found to harbour Zaïre Ebola virus (ZEBOV), mainly non‐human primates and fruit bats. The risk for persons in Europe linked to the transmission of ZEBOV via handling and preparation (by consumers or staff handling the food in kitchens immediately prior to consumption), and consumption of bushmeat illegally imported ...
openaire   +2 more sources

A COMPREHENSIVE STUDY ON EBOLA (EBOV) VIRUS: A THREAT TO HUMAN EXISTENCE

Journal of Drug Delivery and Therapeutics, 2018
Ebola hemorrhagic disease is a severe, an acute, often fatal disease in humans and non-humans which is caused by infection with a virus of family: Filoviridae, genus: Ebola virus. The incubation period of ebola virus disease (EVD) varies from 2-21 days, with an observed average of 8 to 10 days by following introduction of Ebola virus in the human ...
Mani Taneja, Anu Malik, Manisha Singh, Doli Das   +3 more
openaire   +2 more sources

A multiplex interactome of Ebola virus proteins reveals TM9SF2 as a cell‐surface attachment factor that promotes viral entry

iMetaOmics, EarlyView.
This study generates a comprehensive Ebola virus (EBOV)‐human protein–protein interactome, comprising 1728 core high‐confidence interactions. Further interactome analysis revealed the potential association of EBOV glycoprotein (GP) with the host factor TM9SF2. Subsequent mechanistic investigations confirmed that TM9SF2 functions as an attachment factor
Limin Shang, Shouwen Du, Yuchen Liu, Letian Li, Xi Wu, Yanzhi Yuan, Chaozhi Jin, Qingkun Mi, Yuhang Wang, Xiaoshuang Shi, Jiamin Wang, Guoqing Zhang, Yidan Ma, Weijin Huang, Jigang Wang, Jian Wang, Chang Li   +16 more
wiley   +1 more source

Ebola virus (EBOV) infection: Therapeutic strategies

Biochemical Pharmacology, 2015
Within less than a year after its epidemic started (in December 2013) in Guinea, Ebola virus (EBOV), a member of the filoviridae, has spread over a number of West-African countries (Guinea, Sierra Leone and Liberia) and gained allures that have been unprecedented except by human immunodeficiency virus (HIV).
openaire   +2 more sources

Two‐Dimensional Materials For Lateral Flow Assays: A Critical Review of Functional Roles and Translational Challenges

VIEW, EarlyView.
2D nanosheets, with large surface area, excellent optical/electrical properties, and high specificity, combine with lateral flow assay strips to enable rapid, readable detection, boosting the strips’ development and applications. Abstract Lateral flow assays (LFAs) are widely used for point‐of‐care diagnostics, but their detection capability remains ...
Weimin Xu, Ruping Liu, Na Gao, Jianxiao Zhu, Haowen Jiang, Shouzheng Jiao, Zhicheng Sun, Kai Shen, Gaolian Xu, Minghua Du, Ziyan Li, Yang Wang   +11 more
wiley   +1 more source